Contact

JSR-Life-Sciences-deep-blue-gradient-2020APR03

Company Information

 

About JSR Life Sciences


JSR Life Sciences is the large-molecule expert providing the biopharmaceutical industry integrated drug development and manufacturing solutions, from large-scale in vitro and in vivo drug candidate efficacy studies to the clinical and commercial supply of biologics.

We are focused on helping translate our customer’s innovative science into life-saving medicines.

JSR Life Sciences provides high value to the industry by keeping a single chain of custody on our partner’s molecule. We enable our customers to serve patients better with our ability to rapidly advance a large molecule from early experiments all the way to clinical studies. JSR has a global presence with 28 sites and offices in 7 countries.

Expansion in Life Sciences Fields

By converging JSRs leading position in materials innovation with JSR Life Sciences best-in-class companies, the Company is in a unique position to deliver on the promise of digital health by making medicines more personalized and precise.

2012

JSR Life Sciences Corporation

In 2012, JSR established new company called
“JSR Life Sciences Corporation” in acceleration of life sciences business

2015

Amsphere A3

JSR and JSR Life Sciences developed Amsphere™ A3,  a next generation protein A chromatography resin

Learn More

KBI Biopharma

JSR jointly acquired KBI Biopharma, Inc., a contract developer and manufacturers of biopharmaceuticals in the United States

Learn More

2016

MBLI

MBLI becomes a consolidated subsidiary of JSR

Learn More

2017

Selexis SA

Selexis SA becomes consolidated subsidiary of JSR

Learn More

JKiC

JSR-Keio University Medical and Chemical Innovation Center (JKiC) is founded

Learn More

2018

Crown Bioscience

Crown Bioscience International becomes consolidated subsidiary of JSR

Learn More

2019

JSR Life Sciences, LLC

Establishes US Headquarters  for biotechnology and life sciences focused businesses under
the name JSR Life Sciences, LLC effective April 1, 2019